Empagliflozin/metformin regulatory update

Boehringer and Eli Lilly said FDA accepted for review an NDA for empagliflozin/metformin to treat Type II diabetes. The product is a fixed-dose combination of Jardiance empagliflozin, a sodium-glucose cotransporter 2 (SGLT2) inhibitor, and immediate-release metformin. ...